Literature DB >> 32143007

Anti-neuroinflammatory effect of 3,4-dihydroxybenzaldehyde in ischemic stroke.

Xiufang Li1, Bin Xiang1, Ting Shen1, Chun Xiao1, Rong Dai1, Fangyan He1, Qing Lin2.   

Abstract

BACKGROUND: Increasing evidence from human and animal studies suggests that cerebral ischemic diseases are associated with nerve dysfunction and neuroinflammation. Therefore, alleviating neuroinflammation is a potential way to treat ischemic stroke. Gastrodia elata Blume (GEB) is a traditional Chinese medicine used to treat central nervous system diseases and related conditions, such as vertigo, headache, epilepsy. We have previously shown that GEB has a protective effect in ischemic stroke, and that the underlying mechanism is related to anti-neuroinflammation. 3,4-Dihydroxybenzaldehyde (DBD) is a phenolic component of GEB and may be responsible for the neuroprotective effect of GEB; however, the detailed molecular mechanisms underlying the effects of DBD are unknown.
METHODS: The anti-neuroinflammatory effect of DBD and the potential mechanisms underlying it were assessed. We using a rat model of middle cerebral artery occlusion/reperfusion and lipopolysaccharide-treated BV2 microglial cells.
RESULTS: DBD (10 mg/kg) significantly decreased infarct volume. Additionally, it alleviated neurological deficits in the rats by inhibiting microglia activation. DBD (0.01, 0.1, and 1 μM) also significantly decreased the levels of inflammatory mediators and cytokines such as tumor necrosis factor-α, interleukin (IL)-1β, IL-6, prostaglandin E2. Furthermore, phenotypic analysis of the BV2 cells showed that DBD significantly down-regulated the expression of M1 marker but significantly up-regulated the expression of M2 marker. Moreover, it suppressed nuclear factor (NF)-κB activation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase, and extracellular signal-regulated protein kinases 1/2.
CONCLUSIONS: The neuroprotective and anti-inflammatory effects of DBD are associated with selective modulation of microglia polarization and reduction in the production of inflammatory mediators and cytokines through inhibition of MAPK and NF-κB activation. These findings suggest that DBD may be a potential treatment for ischemic stroke and other neuroinflammatory diseases.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3,4-Dihydroxybenzaldehyde; Ischemic stroke; Microglia; Neuroinflammation; Polarization

Year:  2020        PMID: 32143007     DOI: 10.1016/j.intimp.2020.106353

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

Review 1.  Pharmacological and Chemical Potential of Spiranthes sinensis (Orchidaceae): A Narrative Review.

Authors:  Yu-Jen Kuo; Jin-Kuo Pei; Wen-Wan Chao
Journal:  Plants (Basel)       Date:  2022-06-27

2.  Long Non-coding RNA RMST Worsens Ischemic Stroke via MicroRNA-221-3p/PIK3R1/TGF-β Signaling Pathway.

Authors:  Jie Li; Ning Wang; Huan Nie; Shan Wang; Tongtong Jiang; Xuehan Ma; Wenjuan Liu; Kuo Tian
Journal:  Mol Neurobiol       Date:  2022-02-25       Impact factor: 5.682

3.  Tianma Formula Alleviates Dementia via ACER2-Mediated Sphingolipid Signaling Pathway Involving Aβ.

Authors:  Haochang Lin; Sha Wu; Zhiying Weng; Hongyan Wang; Rui Shi; Menghua Tian; Youlan Wang; Haiyan He; Yuchuan Wang; Xuan Liu; Zhimin Jian; Fuqin Wei; Peng Wang; Liuyi Zhang; Yi Liu; Qiuzhe Guo; Chen Chen; Weimin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-04       Impact factor: 2.629

Review 4.  Bone Marrow-Derived NCS-01 Cells Advance a Novel Cell-Based Therapy for Stroke.

Authors:  John Brown; You Jeong Park; Jea-Young Lee; Thomas N Chase; Minako Koga; Cesar V Borlongan
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

Review 5.  Effects of Microglial Activation and Polarization on Brain Injury After Stroke.

Authors:  Rui Dong; Renxuan Huang; Jiaoqi Wang; Hongyu Liu; Zhongxin Xu
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.